by Plus Therapeutics | May 17, 2024 | Uncategorized
Exciting News! Our partner, Head for the Cure Foundation has launched a new patient and caregiver resource, “Join Your Path to Hope!” JPH gives personalized guidance and resources for every step of your brain tumor journey within three different paths: medical,...
by Plus Therapeutics | May 15, 2024 | LM
“Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern...
by Plus Therapeutics | May 10, 2024 | Uncategorized
Thank you to everyone who stopped by our booth at the AANS annual meeting to learn more about our ReSPECT Recurrent Glioblastoma and Leptomeningeal Metastases clinical trials! If you missed us and would like more information, you can send us an email at...
by Plus Therapeutics | May 9, 2024 | LM
Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning’s investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...
by Plus Therapeutics | May 6, 2024 | GBM
➡️ GLIOBLASTOMA PATIENT WEBINAR ⬅️ Join us as the @MusellaFoundation hosts Dr. Andrew Brenner and Dr. Marc Hedrick in a discussion about the ReSPECT-GBM Phase 2 Clinical Trial for Recurrent Glioblastoma. The webinar will take place May 20 2pm EST with a recording to...
Recent Comments